General Information of the m6A Target Gene (ID: M6ATAR00462)
Target Name Non-homologous end-joining factor 1 (NHEJ1/XLF)
Synonyms
Protein cernunnos; XRCC4-like factor; XLF
    Click to Show/Hide
Gene Name NHEJ1
Family XRCC4-XLF family. XLF subfamily. {ECO:0000305}.
Function
DNA repair protein involved in DNA non-homologous end joining (NHEJ); required for double-strand break (DSB) repair and V(D)J recombination. Plays a key role in NHEJ by promoting the ligation of various mismatched and non-cohesive ends. Together with PAXX, collaborates with DNA polymerase lambda (POLL) to promote joining of non-cohesive DNA ends. May act in concert with XRCC5-XRCC6 (Ku) to stimulate XRCC4-mediated joining of blunt ends and several types of mismatched ends that are non-complementary or partially complementary. Associates with XRCC4 to form alternating helical filaments that bridge DNA and act like a bandage, holding together the broken DNA until it is repaired. The XRCC4-NHEJ1/XLF subcomplex binds to the DNA fragments of a DSB in a highly diffusive manner and robustly bridges two independent DNA molecules, holding the broken DNA fragments in close proximity to one other. The mobility of the bridges ensures that the ends remain accessible for further processing by other repair factors . Binds DNA in a length-dependent manner.
    Click to Show/Hide
Gene ID 2956
Uniprot ID
NHEJ1_HUMAN
HGNC ID
HGNC:25737
Ensembl Gene ID
ENSG00000187736
KEGG ID
hsa:79840
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
NHEJ1 can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Browse Drug
Protein virilizer homolog (VIRMA) [WRITER]
In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [1]
Response Summary VIRMA has an oncogenic role in germ cell tumor confirming our previous tissue-based study and is further involved in response to cisplatin by interfering with DNA repair. Enhanced response to cisplatin after VIRMA knockdown was related to significant increase in DNA damage (with higher Gamma-H2AX and GADD45B levels) and downregulation of Non-homologous end-joining factor 1 (NHEJ1/XLF) and MRE11.
Target Regulation Up regulation
Responsed Disease Germ cell tumour of testis ICD-11: 2C80.2
Responsed Drug Cisplatin Approved
In-vitro Model 2102EP Embryonal carcinoma Homo sapiens CVCL_C522
NCC-IT Testicular embryonal carcinoma Homo sapiens CVCL_1451
NT2 Malignant neoplasms Mus musculus CVCL_JA57
TCam-2 Testicular seminoma Homo sapiens CVCL_T012
Testicular cancer [ICD-11: 2C80]
In total 1 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response [1]
Response Summary VIRMA has an oncogenic role in germ cell tumor confirming our previous tissue-based study and is further involved in response to cisplatin by interfering with DNA repair. Enhanced response to cisplatin after VIRMA knockdown was related to significant increase in DNA damage (with higher Gamma-H2AX and GADD45B levels) and downregulation of Non-homologous end-joining factor 1 (NHEJ1/XLF) and MRE11.
Responsed Disease Germ cell tumour of testis [ICD-11: 2C80.2]
Target Regulator Protein virilizer homolog (VIRMA) WRITER
Target Regulation Up regulation
Responsed Drug Cisplatin Approved
In-vitro Model 2102EP Embryonal carcinoma Homo sapiens CVCL_C522
NCC-IT Testicular embryonal carcinoma Homo sapiens CVCL_1451
NT2 Malignant neoplasms Mus musculus CVCL_JA57
TCam-2 Testicular seminoma Homo sapiens CVCL_T012
Cisplatin [Approved]
In total 1 item(s) under this drug
Experiment 1 Reporting the m6A-centered Drug Response [1]
Response Summary VIRMA has an oncogenic role in germ cell tumor confirming our previous tissue-based study and is further involved in response to cisplatin by interfering with DNA repair. Enhanced response to cisplatin after VIRMA knockdown was related to significant increase in DNA damage (with higher Gamma-H2AX and GADD45B levels) and downregulation of Non-homologous end-joining factor 1 (NHEJ1/XLF) and MRE11.
Target Regulator Protein virilizer homolog (VIRMA) WRITER
Target Regulation Up regulation
Responsed Disease Germ cell tumour of testis ICD-11: 2C80.2
In-vitro Model 2102EP Embryonal carcinoma Homo sapiens CVCL_C522
NCC-IT Testicular embryonal carcinoma Homo sapiens CVCL_1451
NT2 Malignant neoplasms Mus musculus CVCL_JA57
TCam-2 Testicular seminoma Homo sapiens CVCL_T012
References
Ref 1 The component of the m(6)A writer complex VIRMA is implicated in aggressive tumor phenotype, DNA damage response and cisplatin resistance in germ cell tumors. J Exp Clin Cancer Res. 2021 Aug 25;40(1):268. doi: 10.1186/s13046-021-02072-9.